Abstract:To explore the categories of drugs causing hepatotoxicity and analyze the clinical and histological features of the corresponding drug-induced liver injury (DILI), in order to gain insights into potential diagnostic factors for DILI.A total of 138 DILI patients treated at our hospital from April 2008 to April 2010 were retrospectively analyzed. The responsible drug for each DILI case was recorded. The Roussel Uclaf Causality Assessment Method (RUCAM) had been used to diagnose DILI. Only cases that had scored as highly probable or probable (more than or equal to 6 points by RUCAM) were included in this study. The patients' general condition, clinical manifestations, and serum biochemical and immunological parameters were assessed. Sixty-six of the patients underwent liver biopsy, and were assessed for liver pathological changes. Clinical and laboratory test data were collected and used to classify the total 138 cases as hepatocellular injury, cholestatic, or mixed hepatocellular-cholestatic types.Within our patient population, the leading cause of DILI was Chinese herb medicine, accounting for 53.62% of cases. Antibiotics were implicated in 7.97% of cases, and dietary supplement in 6.52% of cases. Correlation between the clinical features and histological injury pattern was stronger at the time of biopsy (more than or equal to 3 days after laboratory results) (kappa = 0.63, P less than 0.05) than at the onset of DILI (kappa = 0.25, P less than 0.05). All modified hepatic activity index (HAI) necroinflammatory scores and fibrosis scores were more severe in the cholestatic and mixed injury types than in the hepatocellular injury type (P less than 0.01 and P less than 0.05, respectively).Chinese herbal medicine, dietary supplements and antibiotics were the main causes of DILI in our patient population. The clinical and histological features correlated well, especially at later stages of DILI. The degree of inflammation and fibrosis was significantly higher in cholestatic and mixed hepatocellular-cholestatic injury types than in the hepatocellular injury type. Assessment of both clinical and pathological features may represent a more accurate diagnostic method for DILI.

[Research Progress on Laboratory Diagnosis of Drug-Induced Liver Injury].

Causal Evaluation of Post-Marketing Drugs for Drug-induced Liver Injury from Electronic Health Records*

The Liver Toxicity Knowledge Base (LKTB) and Drug-Induced Liver Injury (DILI) Classification for Assessment of Human Liver Injury

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Current epidemiological study of drug-induced liver injury

A new prognostic model for drug-induced liver injury especially suitable for Chinese population

[Promoting Translational Research on Drug-Induced Liver Injury].

Clinical features of drug-induced liver failure and related diagnosis and treatment strategies

Drug-induced liver injury: a comprehensive review

Clinical features and prognosis of drug -induced liver injury: An analysis of 95 cases

Overview of Research on Drug-induced Liver Injury

[An analysis on clinical characteristics and prognosis-related risk factors in patients with drug-induced liver injury].

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques

Multidisciplinary Expert Consensus on Clinical Features and Prognosis of Drug-Induced Liver Injury

Clinical and pathological features in 138 cases of drug-induced liver injury]

Deep Learning for Drug-Induced Liver Injury.

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Idiosyncratic drug-induced liver injury: an overview

MicroRNAs in Drug-induced Liver Injury.

Clinical Analysis on 41 Case of Drug Induced Liver Injury

Severe Drug-Induced Liver Injury From Over-the-Counter Medication